チロシンプロテインキナーゼJAK2治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0719
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年1月14日
◆ページ数:192
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Tyrosine Protein Kinase JAK2 – Pipeline Review, H1 2020
Summary

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B.

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 33 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 5, 6, 1, 1, 9 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Respiratory, Ophthalmology, Central Nervous System, Gastrointestinal, Metabolic Disorders, Cardiovascular, Genetic Disorders, Hematological Disorders, Infectious Disease, Musculoskeletal Disorders and Women’s Health which include indications Myelofibrosis, Alopecia Areata, Atopic Dermatitis (Atopic Eczema), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Asthma, Graft Versus Host Disease (GVHD), Rheumatoid Arthritis, Chronic Myelomonocytic Leukemia (CMML), Diabetic Macular Edema, Glioblastoma Multiforme (GBM), Myeloproliferative Disorders, Primary Myelofibrosis, Psoriasis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Aicardi-Goutieres Syndrome (AGS), Anaplastic Astrocytoma, Anterior Uveitis, Auto Inflammatory Disease, Autoimmune Disorders, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Breast Hyperplasia, Bronchiolitis Obliterans, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Crohn’s Disease (Regional Enteritis), Dermatitis (Eczema), Dermatomyositis, Diffuse Large B-Cell Lymphoma, Epstein-Barr Virus (HHV-4) Infections, Essential Thrombocythemia, Gastrointestinal Tract Cancer, Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Glaucoma, Gliosarcoma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Inflammation, Inflammatory Bowel Disease, Juvenile Arthritis, Laryngeal Cancer, Leukemia, Lung Transplant Rejection, Metastatic Prostate Cancer, Myelodysplastic Syndrome, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson’s Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Polymyalgia Rheumatica (PMR), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Proliferative Diabetic Retinopathy (PDR), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Solid Tumor, Systemic Idiopathic Juvenile Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thrombocythemia Myelofibrosis, Triple-Negative Breast Cancer (TNBC), Ulcerative Colitis, Vitiligo and Wet (Neovascular / Exudative) Macular Degeneration.

The latest report Tyrosine Protein Kinase JAK2 – Pipeline Review, H1 2020, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Overview
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Companies Involved in Therapeutics Development
Adastra Pharmaceuticals Inc
Aerie Pharmaceuticals Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Celon Pharma SA
CJ HealthCare Corp
Concert Pharmaceuticals Inc
CTI BioPharma Corp
Eli Lilly and Co
Hangzhou East China Pharmaceutical Group Co Ltd
Incyte Corp
Japan Tobacco Inc
Merck & Co Inc
Novartis AG
NS Pharma Inc
OHM Oncology
Pfizer Inc
Sierra Oncology Inc
Simcere Pharmaceutical Group
Suzhou Zelgen Biopharmaceutical Co Ltd
Theravance Biopharma Inc
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Drug Profiles
AR-13503 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1480 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baricitinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHZ-868 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-15314 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPL-407105 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTP-543 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
delgocitinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fedratinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLLL-12 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
jaktinib hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-2014 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
momelotinib dihydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-018 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OB-756 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OHM-581 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pacritinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-317461 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AURKA, EGFR and JAK2 for Gastrointestinal Tract Cancer – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK2 for Leukemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAKs for Lung Transplant Rejection – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK1, JAK2, JAK3 and TYK2 for Dermatology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 and FLT3 for Myelofibrosis and Acute Myeloid Leukemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Moleucle to Inhibit JAK 1 and JAK 2 for Inflammation – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-1473 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-8236 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zotiraciclib citrate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Dormant Products
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Discontinued Products
Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Product Development Milestones
Featured News & Press Releases
Appendix

List of Tables
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Adastra Pharmaceuticals Inc, H1 2020
Pipeline by Aerie Pharmaceuticals Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Celon Pharma SA, H1 2020
Pipeline by CJ HealthCare Corp, H1 2020
Pipeline by Concert Pharmaceuticals Inc, H1 2020
Pipeline by CTI BioPharma Corp, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, H1 2020
Pipeline by Incyte Corp, H1 2020
Pipeline by Japan Tobacco Inc, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by NS Pharma Inc, H1 2020
Pipeline by OHM Oncology, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Sierra Oncology Inc, H1 2020
Pipeline by Simcere Pharmaceutical Group, H1 2020
Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, H1 2020
Pipeline by Theravance Biopharma Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020
Dormant Products, H1 2020 (Contd..4), H1 2020
Dormant Products, H1 2020 (Contd..5), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020

【掲載企業】

Adastra Pharmaceuticals Inc
Aerie Pharmaceuticals Inc
AstraZeneca Plc
Bristol-Myers Squibb Co
Celon Pharma SA
CJ HealthCare Corp
Concert Pharmaceuticals Inc
CTI BioPharma Corp
Eli Lilly and Co
Hangzhou East China Pharmaceutical Group Co Ltd
Incyte Corp
Japan Tobacco Inc
Merck & Co Inc
Novartis AG
NS Pharma Inc
OHM Oncology
Pfizer Inc
Sierra Oncology Inc
Simcere Pharmaceutical Group
Suzhou Zelgen Biopharmaceutical Co Ltd
Theravance Biopharma Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[チロシンプロテインキナーゼJAK2治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆